TrialJournal of hematology & oncology2023
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Qian Jiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.